Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 429-433

  Saarto, T ^a   Blomqvist, C ^a   Ehnholm, C ^a   Taskinen, M R ^a   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY RISK; DRUG EFFECT; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LUTEINIZING HORMONE BLOOD LEVEL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0030033913     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.429     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71-85, 1992
3. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435-437, 1991
4. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993
5. Walsh BW, Schiff I, Rosner B, et al: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991
6. Sacks FM, McPherson R, Walsh BW: Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 154:1106-1110, 1994
7. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990
8. Powles TJ, Tillyer CR, Jones AL, et al: Prevention of breast cancer with tamoxifen - An update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26:680-684, 1990
9. Dewar JA, Horobin JM, Preece PE, et al: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305:225-226, 1992
10. Tikkanen MJ, Nikkilä EA: Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 113:562-567, 1987
11. Seed M, Crook D: Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 5:48-58, 1994
12. Loscalzo J: Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 10:672-679, 1990
13. Utermann G: Lipoprotein (a): A genetic risk factor for premature coronary heart disease. Curr Opin Lipidol 1:404-410, 1990
14. Sandholzer C, Saha N, Kark JD, et al: Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12:1214-1226, 1992
15. Gotto AJ: Postmenopausal hormone-replacement therapy, plasma lipoprotein[a], and risk for coronary heart disease. J Lab Clin Med 123:800-803, 1994 (editorial)
16. Sacks FM, Walsh BW: Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 5:236-240, 1994
17. Nabulsi AA, Folsom AR, White A, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069-1075, 1993
18. Shewmon DA, Stock JL, Rosen CJ, et al: Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb 14:1586-1593, 1994
19. Valavaara R, Pyrhönen S, Heikkinen M, et al: Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24:785-790, 1988
20. Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer - A double-blind crossover trial. Breast Cancer Res Treat 25:57-63, 1993
21. Kangas L, Nieminen AL, Blanco G, et al: A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17:109-113, 1986
22. Kendall ME, Rose DP: The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114:127-131, 1992
23. Szamel I, Vincze B, Hindy I, et al: Hormonal effects of toremifene in breast cancer patients. J Steroid Biochem 136:243-247, 1990
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the Concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
25. Jauhiainen M, Koskinen P, Ehnholm C, et al: Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59-67, 1991
26. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
27. Fruchart JC, Ailhaud G: Apolipoprotein A-containing lipoprotein particles: Physiological role, quantification, and clinical significance. Clin Chem 38:793-797, 1992
28. Walsh BW, Li H, Sacks FM: Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35:2083-2093, 1994
29. Srivastava RA, Baumann D, Schonfeld G: In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem 216:527-538, 1993
30. Kraft HG, Sandholzer C, Menzel HJ, et al: Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma. Arterioscler Thromb 12:302-306, 1992
31. Rader DJ, Cain W, Ikewaki K, et al: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 93:2758-2763, 1994
32. Rader DJ, Cain W, Zech LA, et al: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 91:443-447, 1993
33. Lipid Research Clinical Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. reduction in increase of coronary heart disease. JAMA 251:351-364, 1984
34. Gordon DJ, Probstfield JL, Garrison RJ, et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989